Adults 18 to 55, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants Experiencing an Adverse Event (AE)Primary· Up to approximately 17 days
An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one or more AEs were reported.
Group
Value
95% CI
Panel A MK-8189 48 mg
3
Panel A MK-8189 60mg
2
Panel A Placebo
0
Panel A-1 MK-8189 48 mg
3
Panel A-1 MK-8189 80 mg
4
Panel A-1 Placebo
0
Panel C MK-8189 48 mg
7
Panel C MK-8189 80 mg
6
Panel C Placebo
6
Number of Participants Who Discontinue From Study Treatment Due to an AEPrimary· Up to approximately 3 days
An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study due to an AE were reported.
Group
Value
95% CI
Panel A MK-8189 48 mg
0
Panel A MK-8189 60mg
0
Panel A Placebo
0
Panel A-1 MK-8189 48 mg
0
Panel A-1 MK-8189 80 mg
0
Panel A-1 Placebo
0
Panel C MK-8189 48 mg
1
Panel C MK-8189 80 mg
0
Panel C Placebo
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to approximately 17 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT06273774 — A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)
· Phase 1
· completed
NCT05953740 — A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
· Phase 1
· completed
NCT05893862 — A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophre
· Phase 1
· completed
NCT05227118 — MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggressio
· Phase 1
· completed
NCT04676425 — A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)
· Phase 1
· completed
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au
· Phase 3
· recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
· Phase 2
· recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
· recruiting
NCT06758414 — CBT-CP for Veterans With SMI
· NA
· recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis
· NA
· recruiting
Other Merck Sharp & Dohme LLC trials
Trials by the same sponsor.
NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005)
· Phase 2
· not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan
· Phase 1, PHASE2
· recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527
· Phase 1
· not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M
· Phase 3
· not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti
· Phase 1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 25 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05406440.